Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

Inclusion Criteria

• •1. Male and female outpatients older than 18 and younger than 55 years of age.
• •2. Subjects with the diagnosis of attention deficit hyperactivity disorder not otherwise specified (ADHD NOS), by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), as manifested in clinical evaluation and confirmed by structured interview. This is operationalized by either:
• •1. having currently at least 6/9 current items of either inattention or hyperactivity/impulsivity but \< 5 items from either list in childhood; or
• •2. having 5 out of 9 current DSM-IV items of inattention and/or hyperactivity/impulsivity, but not having 6 current symptoms in either category. This second category will be included independent of the presence or absence of ADHD symptoms in childhood.
• •3. Subjects will have a current Clinical Global Impression ADHD score of 4 or higher.
• •4. Subjects with past history of depression or anxiety disorder (including obsessive compulsive disorder \[OCD\]) without current disorder for \> 3 months as ascertained through structured diagnostic interview and clinical exam will be allowed to participate.
• •5. Subjects treated for anxiety disorders and depression who are on a stable medication regimen for at least three months, and who have a disorder specific CGI-severity score ≤ 3 (mildly ill) and who have a score on the Hamilton-depression and Hamilton-anxiety rating scale below 15 (mild range) will be included in the study.
• •6. Subjects with past history of substance use disorders but have been asymptomatic for at least 6 months and have a negative drug screen will be allowed to participate.
• •7. Subjects receiving non-monoamine oxidase inhibitor (MAOI) antidepressants (e.g., selective serotonin reuptake inhibitors \[SSRIs\], bupropion, venlafaxine), or benzodiazepines who have been on a stable regimen for \> 3 months for any of the conditions listed above.
• •8. Subjects with mild cases of asthma and allergy will be allowed to participate.
• •9. Subjects with acid reflux syndrome will be allowed to participate.
• •10. Subjects with hypercholesterolemia who are on a stable dose of cholesterol-lowering medication will be allowed to participate.